![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Two applications claiming novel long-acting β2 agonists provide new analogues of salmeterol and formoterol, respectively. The first claims salmeterol derivatives in which the terminal phenyl group bears an imidazolidinedione substituent, the second combines the head group employed in formoterol with a sulfonamido substituted tail portion of salmeterol.